Open Access

SGLT2 inhibitors and heart failure in the cardiorenal spectrum

Event: ESC Congress 2021 - The Digital Experience
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Organised by CHANGE IME supported by an unrestricted educational grant from AstraZeneca
Date: 29 August 2021
Time: 19:00 - 19:30

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

3 presentations in this session

Heart failure in context.

Speaker: Professor C. Linde (Stockholm, SE)

SGLT2 Inhibitors as a Central Cardio-Renal-Metabolic Therapy: The Modern Day ACE Inhibitor.

Speaker: Doctor M. Vaduganathan (Boston, US)

Treating the whole spectrum of heart failure.

Speaker: Professor G. Rosano (London, GB)

3 speakers from this session

Professor Cecilia Linde

Karolinska Institutet, Stockholm (Sweden)
44 presentations
1 follower

Doctor Muthiah Vaduganathan

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
9 presentations
0 follower

Professor Giuseppe M C Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)
64 presentations

Related content

ESC Premium Access

Management of diabetes mellitus in patients with cardiovascular disease

3 December 2021

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk